Edwards Lifesciences Co. (NYSE:EW) Shares Purchased by Vestcor Inc

Vestcor Inc raised its holdings in Edwards Lifesciences Co. (NYSE:EW) by 44.8% in the 4th quarter, Holdings Channel reports. The institutional investor owned 15,793 shares of the medical research company’s stock after acquiring an additional 4,887 shares during the period. Vestcor Inc’s holdings in Edwards Lifesciences were worth $1,169,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the stock. Connor Clark & Lunn Investment Management Ltd. grew its position in Edwards Lifesciences by 77.9% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 380,103 shares of the medical research company’s stock valued at $28,139,000 after acquiring an additional 166,403 shares during the period. Avantax Advisory Services Inc. lifted its stake in shares of Edwards Lifesciences by 12.1% in the 4th quarter. Avantax Advisory Services Inc. now owns 9,675 shares of the medical research company’s stock valued at $716,000 after purchasing an additional 1,043 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of Edwards Lifesciences by 27.6% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,304 shares of the medical research company’s stock worth $97,000 after purchasing an additional 282 shares during the period. Sequoia Financial Advisors LLC grew its holdings in shares of Edwards Lifesciences by 17.0% during the 4th quarter. Sequoia Financial Advisors LLC now owns 8,078 shares of the medical research company’s stock worth $598,000 after purchasing an additional 1,176 shares during the period. Finally, Moors & Cabot Inc. increased its position in Edwards Lifesciences by 0.3% during the 4th quarter. Moors & Cabot Inc. now owns 54,589 shares of the medical research company’s stock worth $4,041,000 after purchasing an additional 152 shares in the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 400 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $69.48, for a total transaction of $27,792.00. Following the completion of the transaction, the vice president now owns 22,588 shares in the company, valued at $1,569,414.24. The trade was a 1.74 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of the company’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total value of $852,300.00. Following the transaction, the chief financial officer now owns 30,561 shares of the company’s stock, valued at approximately $2,315,301.36. The trade was a 26.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 53,803 shares of company stock valued at $3,900,976 in the last quarter. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Trading Up 2.1 %

NYSE:EW opened at $69.37 on Friday. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The company has a market cap of $40.78 billion, a PE ratio of 9.95, a P/E/G ratio of 4.82 and a beta of 1.12. The business’s 50 day moving average is $71.74 and its two-hundred day moving average is $70.33.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Wolfe Research lowered shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 12th. Morgan Stanley increased their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a report on Wednesday, February 12th. Citigroup boosted their price objective on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Piper Sandler increased their target price on Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research note on Wednesday, February 12th. Finally, Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $82.00 to $90.00 in a research report on Monday, December 16th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.